Edition:
United States

MannKind Corp (MNKD.OQ)

MNKD.OQ on NASDAQ Stock Exchange Global Market

1.30USD
10:44am EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$1.30
Open
$1.29
Day's High
$1.33
Day's Low
$1.26
Volume
70,830
Avg. Vol
397,709
52-wk High
$6.47
52-wk Low
$0.67

MNKD.OQ

Chart for MNKD.OQ

About

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic... (more)

Overall

Beta: 3.34
Market Cap(Mil.): $131.31
Shares Outstanding(Mil.): 101.01
Dividend: --
Yield (%): --

Financials

  MNKD.OQ Industry Sector
P/E (TTM): 0.95 141.11 17.36
EPS (TTM): 1.37 -- --
ROI: -- 2.25 -5.72
ROE: -- 0.17 -5.10

BRIEF-Mannkind Corporation reports Q1 revenue $3.0 million

* Mannkind Corporation reports 2017 first quarter financial results

May 10 2017

BRIEF-James Flynn reports 5.17 pct passive stake in Mannkind Corp as of April 19 - SEC Filing

* James Flynn reports 5.17 percent passive stake in Mannkind Corp as of April 19 - SEC Filing Source text: [http://bit.ly/2pBirgj] Further company coverage:

Apr 19 2017

BRIEF-Mannkind's unit entered exchange agreement

* Mannkind - on April 18 co, unit entered exchange agreement with Deerfield Private Design Fund II, and Deerfield Private Design International II

Apr 19 2017

BRIEF-Mannkind qtrly net income per share - diluted 56 cents

* Mannkind Corporation reports 2016 fourth quarter and full year financial results

Mar 16 2017

BRIEF-MannKind launches new titration pack and field force expansion to accelerate Afrezza growth

* MannKind announces launch of new titration pack and field force expansion to accelerate Afrezza growth

Feb 01 2017

BRIEF-Mannkind entered into agreement of purchase and sale and joint Escrow Instructions with Rexford Industrial Realty - SEC Filing

* Mannkind - On Jan 6, 2017, co entered into agreement of purchase and sale and joint Escrow Instructions with Rexford Industrial Realty - SEC Filing

Jan 12 2017

BRIEF-MannKind says receives $30.6 million from Sanofi

* MannKind receives $30.6 million from Sanofi Source text for Eikon: Further company coverage:

Jan 09 2017

More From Around the Web

Competitors

  Price Chg
Novo Nordisk A/S (NOVOb.CO) kr.276.70 -0.60
Pfizer Inc. (PFE.N) $32.22 +0.09
Sanofi SA (SASY.PA) €87.61 -0.21
Eli Lilly and Co (LLY.N) $78.11 +0.12
Nektar Therapeutics (NKTR.OQ) $20.56 +0.81
Albireo Pharma Inc (ALBO.OQ) $20.54 -0.67

Earnings vs. Estimates